• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, October 5, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Stopping aspirin three months after stenting does not increase risk of death

Bioengineer by Bioengineer
March 18, 2019
in Health
Reading Time: 4 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Study suggests doctors can balance clotting, bleeding risks with P2Y12 inhibitor drugs alone

Patients who stopped taking aspirin three months after receiving a stent to open the heart’s arteries but continued taking a P2Y12 inhibitor–clopidogrel, prasugrel or ticagrelor–did not experience higher rates of death from any cause, heart attack or stroke after a year compared with those receiving standard therapy, according to research presented at the American College of Cardiology’s 68th Annual Scientific Session. Furthermore, patients who stopped taking aspirin after three months had a significantly lower rate of bleeding.

The trial, known as SMART-CHOICE, comes as doctors seek to determine what drug combinations offer the best complement with the latest generation of drug-eluting stents–small mesh tubes used to open blocked arteries that release drugs to prevent new blockages from forming around the stent. After undergoing a procedure known as percutaneous coronary intervention (PCI) to insert a stent, patients can be at risk for adverse events related to clotting, including heart attack and stroke. For this reason, antiplatelet medications are used to reduce the body’s ability to clot blood, but they also raise the risk of uncontrolled bleeding.

Current guidelines recommend balancing these risks by prescribing aspirin and one of three P2Y12 inhibitors for at least 12 months when a patient receives a stent after a heart attack (or six months for patients receiving a stent for angina), a strategy known as dual antiplatelet therapy (DAPT). The new trial assessed whether stopping aspirin after three months but continuing the P2Y12 inhibitor alone for 12 months would offer better results.

“Our study demonstrated that P2Y12 inhibitor monotherapy after a short duration of DAPT is a novel antiplatelet strategy balancing ischemic and bleeding risk in patients undergoing PCI,” said Joo-Yong Hahn, MD, PhD, professor of medicine at Sungkyunkwan University School of Medicine in Seoul, South Korea and the study’s lead author. “Even though this treatment strategy needs to be confirmed in other trials, aspirin may be discontinued in most patients receiving current-generation drug-eluting stents, especially in patients with bleeding risk or in those with stable ischemic heart disease.”

The trial enrolled 2,993 patients who underwent PCI and received a drug-eluting stent at 33 medical centers in South Korea. Patients were randomly assigned to receive either standard DAPT for a year or aspirin plus a P2Y12 inhibitor for three months and continue with only the P2Y12 inhibitor for nine more months after that.

After one year, 2.9 percent of patients who stopped aspirin early experienced the primary endpoint, a composite of death from any cause, heart attack or stroke, compared to 2.5 percent among those following standard DAPT. Based on thresholds determined before the trial began, these rates indicate that stopping aspirin early was not inferior to DAPT in terms of the trial’s primary endpoint.

In addition, stopping aspirin early was found to reduce the risk of bleeding by about 40 percent. Overall, 2 percent of those stopping aspirin experienced major bleeding compared to 3.4 percent among those following standard DAPT. Taken together, the net rate of all adverse clinical events (death from any cause, heart attack, stroke or bleeding) was not significantly different between the two groups.

A little more than three-quarters of the study participants took clopidogrel, the most common P2Y12 inhibitor, with the rest taking either prasugrel or ticagrelor. Hahn said that the trial’s inclusion of different P2Y12 inhibitors distinguishes it from other trials investigating alternatives to DAPT.

“The SMART-CHOICE trial has a unique design to include all kinds of P2Y12 inhibitors, including clopidogrel, prasugrel and ticagrelor,” Hahn said. “Therefore, we believe that the SMART-CHOICE trial, compared with several ongoing trials on P2Y12 inhibitor monotherapy after PCI, provides more generalizable answers to the concept of P2Y12 inhibitor monotherapy across a broad spectrum of patients receiving current-generation drug-eluting stents.”

One limitation of the study is that a considerable proportion of patients in the group assigned to stop aspirin early in fact received aspirin after three months, although a more detailed analysis suggested this discrepancy did not undermine the overall findings. Another limitation is that the trial allowed patients to know which medications they had been assigned to take, rather than giving some patients a placebo.

The researchers will further analyze the data to determine whether the type of P2Y12 inhibitor used or variables reflecting patients’ physiological response to the P2Y12 inhibitor may affect outcomes. In addition, they are investigating whether the risk of ischemic events varied among patients with acute coronary syndrome versus stable ischemic heart disease.

###

This study received funding from the Korean Society of Interventional Cardiology, Abbott Vascular, Biotronik and Boston Scientific.

The ACC’s Annual Scientific Session will take place March 16-18, 2019, in New Orleans, bringing together cardiologists and cardiovascular specialists from around the world to share the newest discoveries in treatment and prevention. Follow @ACCinTouch, @ACCMediaCenter and #ACC19 for the latest news from the meeting.

The American College of Cardiology envisions a world where innovation and knowledge optimize cardiovascular care and outcomes. As the professional home for the entire cardiovascular care team, the mission of the College and its more than 52,000 members is to transform cardiovascular care and to improve heart health. The ACC bestows credentials upon cardiovascular professionals who meet stringent qualifications and leads in the formation of health policy, standards and guidelines. The College also provides professional medical education, disseminates cardiovascular research through its world-renowned JACC Journals, operates national registries to measure and improve care, and offers cardiovascular accreditation to hospitals and institutions. For more, visit acc.org.

Media Contact
Nicole Napoli
[email protected]

Tags: CardiologyClinical TrialsMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Magnetic Auricular Acupuncture Eases Newborn Eye Exam Pain

October 5, 2025

EZH2 modulates T cell activation in liver cancer

October 5, 2025

Per Diem Payments: Effects on Mental Health Care Quality

October 4, 2025

New Study Reveals Metabolically Active Visceral Fat Drives Aggressiveness in Endometrial Cancer

October 4, 2025
Please login to join discussion

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    94 shares
    Share 38 Tweet 24
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    91 shares
    Share 36 Tweet 23
  • Physicists Develop Visible Time Crystal for the First Time

    75 shares
    Share 30 Tweet 19
  • New Insights Suggest ALS May Be an Autoimmune Disease

    70 shares
    Share 28 Tweet 18

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Magnetic Auricular Acupuncture Eases Newborn Eye Exam Pain

EZH2 modulates T cell activation in liver cancer

Harnessing Pleiotropy to Improve Variant Discovery Accurately

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 62 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.